Analysis of risk factors and development of a predictive model for significant serum creatinine elevation in patients administered SGLT2 inhibitor in a real-world clinical setting in China

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are widely used, but may lead to significant serum creatinine elevation ( > 30%), posing a risk of acute kidney injury.